Annual General Meeting 2016 in Karo Pharma AB (publ)

STOCKHOLM, Sweden, May 12, 2016 – At today’s Annual General Meeting in Karo
Pharma the following main resolutions were passed.
The AGM voted in favour of adopting the income statements and balance sheets for
the Group and the parent company, and decided that fund at the disposal of the
general meeting, amounting to SEK 359,757,654, including the loss for the year
amounting to SEK – 61,685,826, should be carried forward. Thus, it was resolved
that no dividend should be paid for the financial year 2015.

The AGM further discharged the Board members and the CEO from liability, re
-elected the ordinary board members Anders Lönner, Thomas Hedner, Per-Anders
Johansson and Jean Lycke. Anders Lönner was elected Chairman of the Board.

The AGM resolved that the Board shall consist of four ordinary members and no
deputy members.

The AGM further resolved in accordance with the Board’s proposal on amendment of
the articles of association.

The AGM resolved that the Board’s fees shall remain unchanged at SEK 420,000 for
the Chairman of the Board and SEK 150,000 for each of the other members of the
Board.

The accounting firm PricewaterhouseCoopers AB was re-elected as the company’s
auditor until the AGM 2017.

The AGM resolved in accordance with the proposal of the nomination committee on
principles for the nomination committee.

The AGM also resolved in accordance with the Board’s proposal on guidelines for
remuneration of executive management.

Lastly, the Board was authorized to, on one or several occasions prior to the
next annual general, resolve on new share issues. The number of shares to be
issued by virtue of the authorization shall not exceed 10 per cent of the
registered share capital (at the time of the share issue resolution). The new
share may be made with our without deviation from the shareholders’ pre-emption
right and with or without terms of issue in kind or set-off or other terms.

For further information, please contact:
Henrik Palm, CFO, mobile phone +46 70 540 40 14 or e-mail
henrik.palm@karopharma.se

About Karo Pharma
Karo Pharma is a health care company focused on developing and marketing of
products to pharmacies, fast-moving consumer goods and the fealth care directly.
Karo Pharma is listed on Nasdaq Stockholm.

Karo Pharma publishes this information in accordance with the Swedish Securities
Markets Act. The information was submitted for publication on May 12, 2016, at
9:00 pm CET.

This press release is also available at www.karopharma.com and
www.newsroom.cision.com